Today's Trend
Astria Therapeutics, Inc. (NASDAQ:ATXS) — shares are trading higher today amid fresh analyst activity. The move appears driven by a batch of analyst model updates: Wedbush issued multiple small downward EPS revisions across 2025–2026 quarters while Cantor Fitzgerald issued mixed changes. Both firms keep a "Neutral" stance, leaving headline sentiment balanced but slightly tilted negative because of the downward earnings revisions.
- Cantor Fitzgerald trimmed the magnitude of its FY2026 loss (from -$2.34 to -$2.25 per share), a modest improvement that could be read as slightly supportive for the stock because it implies a better-than-previously-modeled recovery trajectory. Cantor remains Neutral on ATXS.
- Both Wedbush and Cantor Fitzgerald left their ratings unchanged (Wedbush: Neutral, $13 target; Cantor: Neutral). Unchanged ratings and price targets limit the likelihood of major analyst-driven sentiment swings absent new clinical or commercial news.
- Media roundup noting mixed analyst views highlights the conflicting signals investors face — downward revisions from one shop vs. modestly improved modeling from another. Article Title
- Wedbush cut multiple near-term and full-year EPS estimates (Q4 2025–Q4 2026, FY2025 and FY2026) by small increments (mostly a few cents per quarter), and also reduced FY2025/FY2026 forecasts materially versus prior numbers. Those downgrades suggest a slower path to profitability and are a near-term negative for sentiment.
- Cantor also lowered its FY2025 EPS view (from -$2.04 to -$2.26), reinforcing downside risk for near-term profitability expectations despite its slightly improved FY2026 projection.
Bottom line for investors: the market reaction reflects mixed analyst revisions — small model-driven negatives from Wedbush and mixed calls from Cantor — with unchanged Neutral ratings keeping analyst conviction muted. Watch for company-level catalysts (clinical, revenue, or guidance) to move the stock beyond these estimate-driven swings.